Skip to content Skip to footer
0 items - $0.00 0
Complete Omics
0 items - $0.00 0
Complete Omics

Selected Important Publications by Complete Omics

Close

Therapeutic Target Identification (using Valid-NEO or others)

Breaking the “Undruggable”: TP53 Neoantigens Identified

Science. 2021 Mar 5; 371(6533): eabc8697.
Targeting a neoantigen derived from a common TP53 mutation.

Valid-NEO

Breaking the “Undruggable”: KRAS Neoantigens Identified

Science Immunology. 2021 Mar 1; 6(57): eabd5515.
Bispecific antibodies targeting mutant RAS neoantigens.

Valid-NEO

Unlocking a New Class of Cancer Targets: HERV Neoantigens

Science Advances. 2022 Jan 28; 8(4): eabj3671.
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy.

Valid-NEO

Prediction-Free, Totally Data-Driven Neoantigen Discovery: The Valid-NEO Platform

Cancers. 2022 Feb 28; 14(5): 1243.
Valid-NEO: A multi-omics platform enabling highly sensitive neoantigen detection and quantification directly from experimental data without reliance on prediction algorithms.

Valid-NEO

Expanding Immunotherapy Targets: Shared Graft-Versus-Leukemia Antigens Identified

Blood Advances. 2022 Dec 9; 7(9): 1635–1649.
Discovery of shared minor histocompatibility antigens enabling graft-versus-leukemia targeting across transplant recipients.

Valid-NEO

First Direct Detection of Cancer Neoantigens: The Prototype of Valid-NEO

Cancer Immunology Research. 2019 Nov; 7(11): 1748–1754.
Direct detection and quantification of tumor neoantigens using mass spectrometry-based immunopeptidomics, establishing the prototype of the Valid-NEO platform.

Valid-NEO

Opening New Immunotherapy Targets: HERV-Derived Tumor Epitopes in Ovarian Cancer

Journal for Immunotherapy of Cancer. 2025 Aug 3; 13(8): e010099.
HERV-derived epitopes represent a new class of shared tumor antigens enabling T-cell–based immunotherapies in ovarian cancer.

Valid-NEO

Biomarker and Liquid Biopsy (i.e. Complete360)

Benchmarking Mainstream Proteomics Platforms: Complete360 Reveals the Deepest Blood Proteome

bioRxiv [Preprint]. 2025 May 20: 2025.05.15.654311.
Systematic comparison across major mass spectrometry–based proteomics platforms demonstrating that Complete360 provides the deepest coverage of the human blood proteome.

Liquid Omics

First Clinical Application of Complete360: Deep Proteomics Reaches 10,000 Proteins per Patient

Cell. 2025 Aug 7; 188(16): 4225–4238.e12.
First clinical application of the Complete360 platform achieving ~10,000 proteins per patient sample in a CAR-NK therapy study.

Liquid Omics
Science [Accepted]. 2026 March Severe Obesity in Human HFpEF Alters Contractile Protein Function and Organization.
Biomarkers

A Paradigm Shift in Cancer Biomarkers: An Early Prototype of Complete360

Proceedings of the National Academy of Sciences (PNAS). 2011 Feb 8; 108(6): 2444–2449.
Targeted clinical proteomics enabling ultra-sensitive quantification of mutant cancer biomarkers from single cells and body fluids.

Liquid Omics

Ultra-Sensitive Targeted Proteomics: An Early Prototype of Complete360

Proceedings of the National Academy of Sciences (PNAS). 2017 Dec 19; 114(51): 13519–13524.
Recursive optimization of targeted proteomics demonstrating substantially higher sensitivity than profiling-level platforms.

Liquid Omics

Situationally Optimized Proteomics with Complete360 Reveals DLAT Methylation in Cancer Metabolism

Nature Communications. 2025 Jan 30; 16(1): 1191.
Application of the Complete360 platform enabling situational-awareness–guided targeted detection of a protein and its PTM, revealing DLAT methylation controlling pyruvate dehydrogenase activity and prostate cancer growth.

Biomarkers